Multiple Effects of Intravitreal Aflibercept on Microvascular Regression in Eyes with Diabetic Macular Edema

Published on Dec 1, 2019in Ophthalmology Retina
· DOI :10.1016/J.ORET.2019.06.005
Masahiko Sugimoto16
Estimated H-index: 16
(Mie University),
Atushi Ichio2
Estimated H-index: 2
(Mie University)
+ 4 AuthorsMineo Kondo55
Estimated H-index: 55
(Mie University)
Sources
Abstract
Abstract Purpose To evaluate the effects of intravitreal aflibercept (IVA) on the microaneurysms (MAs) and sizes of non-perfused areas (NPAs) in eyes with diabetic macular edema (DME). Design Interventional, prospective study. Participants Twenty-five eyes of 25 DME patients (average age, 64.0±8.8 years) were treated with 3 consecutive monthly IVA injections. Methods Fluorescein angiography (FA) and optical coherence tomography were performed prior to the IVA injections(baseline) and at 1 week after the IVA treatment. The number of MAs and the ischemic index (ISI), a measure of the NPAs, were determined. The correlations between central retinal thickness (CRT) and number of MAs and the ISI were also determined. Main Outcome Measures The mean number of MAs and NPA evaluated as the ISI. Results At the baseline, the mean central retinal thickness (CRT) was 485.7±90.6 μm. After treatment, the mean CRT was significantly reduced to 376.9±81.6 μm ( P =0.1 x10 -5 ; repeated ANOVA). The mean number of MAs was significantly decreased from 49.6±33.2 at the baseline to 24.8±18.1 at 3 months after the initial treatment. This was a 50.4±21.2% reduction ( P =0.3 x10 -5 , paired t tests). The mean ISI was also significantly decreased from 55.5±20.4% at the baseline to 28.8±16.8% after the treatment ( P =0.3 x10 -5 , paired t test). This was a reduction of 43.3±28.5%. A significant correlation was found between the CRT and number of MAs at both the baseline (r=0.56, P =0.004) and after the treatment (r=0.53, P =0.006). A significant correlation was found between the CRT and the ISI at the baseline (r=-0.39, P =0.03) but not after the treatment (r=-0.06, P =0.79). Conclusions The reduction in the number of MAs was correlated with the reduction in the CRT.
📖 Papers frequently viewed together
1 Author (S Lee)
References45
Newest
#7M Yaseri (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 20
Click here to listen to the Podcast Background/aims To compare the efficacy of combined intravitreal injection of bevacizumab and a Rho-kinase inhibitor, fasudil (intravitreal bevacizumab (IVB)/intravitreal fasudil (IVF)), with IVB alone for centre-involving diabetic macular oedema (DME). Methods In this prospective randomised clinical trial, 44 eyes with centre-involving DME were randomised into two groups. The combined group received three consecutive injections of IVB (1.25 mg) and IVF (50 µM...
Source
#1Charles C. Wykoff (Cornell University)H-Index: 4
#2David A Eichenbaum (USF: University of South Florida)H-Index: 8
Last. Zdenka Haskova (Genentech)H-Index: 9
view all 6 authors...
Purpose To evaluate diabetic retinopathy (DR) outcomes with ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA) treatment in patients with DR and diabetic macular edema (DME) at high risk of progression to proliferative disease. Design Post hoc analysis of the phase 3 RIDE ( ClinicalTrials.gov identifier, NCT00473382 ) and RISE ( ClinicalTrials.gov identifier, NCT00473330 ) clinical trials of ranibizumab for the treatment of DME. Participants Seven hundred forty-six patients with ba...
Source
#1Paul MitchellH-Index: 54
#2Ian L. McAllister (UWA: University of Western Australia)H-Index: 39
Last. Frank G. Holz (University of Bonn)H-Index: 91
view all 15 authors...
Purpose To evaluate the impact of intravitreal aflibercept (EYLEA, Regeneron Pharmaceuticals, Tarrytown, NY) versus laser on progression of diabetic retinopathy (DR) severity in Intravitreal Aflibercept Injection in Vision Impairment due to DME (VIVID-DME) and Study of Intravitreal Aflibercept Injection in Patients with Diabetic Macular Edema (VISTA-DME). Design Secondary and exploratory analyses of 2 phase 3, randomized, controlled studies. Participants All patients with a baseline Diabetic Ret...
Source
#1David M. Brown (Cornell University)H-Index: 17
#2William C. OuH-Index: 10
Last. Charles C. Wykoff (Cornell University)H-Index: 43
view all 6 authors...
Purpose To evaluate the effect of targeted retinal photocoagulation (TRP) on visual and anatomic outcomes and treatment burden in eyes with diabetic macular edema (DME). Design Phase I/II prospective, randomized, controlled clinical trial. Participants Forty eyes of 29 patients with center-involved macular edema secondary to diabetes mellitus. Methods Eyes with center-involved DME and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) between 20/32 and 20/320 ...
Source
#1Masahiko SugimotoH-Index: 16
#2Atsushi IchioH-Index: 3
Last. Mineo KondoH-Index: 55
view all 4 authors...
To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME). Retrospective, single-center study. For this retrospective study, 42 eyes of 42 patients were initially treated with 3 consecutive monthly IVB injections (loading phase), after which they were selected for different additional therapies. For the TAE protocol, the baseline treatment interval was selected to be 8 weeks and was sequentially lengthened by 2 ...
Source
#1Michael J Allingham (Duke University)H-Index: 14
#2Dibyendu Mukherjee (Duke University)H-Index: 10
Last. Sina Farsiu (Duke University)H-Index: 60
view all 7 authors...
We use semiautomated segmentation of fluorescein angiography (FA) to determine whether anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME) differentially affects microaneurysm (MA)-associated leakage, termed focal leakage, versus non-MA-associated leakage, termed diffuse leakage.We performed a retrospective study of 29 subjects treated with at least three consecutive injections of anti-VEGF agents for DME (mean 4.6 injections; range, 3-10) who underwent Heid...
Source
OBJECTIVE: With the increasing prevalence of diabetes, annual screening for diabetic retinopathy (DR) by expert human grading of retinal images is challenging. Automated DR image assessment systems (ARIAS) may provide clinically effective and cost-effective detection of retinopathy. We aimed to determine whether ARIAS can be safely introduced into DR screening pathways to replace human graders. DESIGN: Observational measurement comparison study of human graders following a national screening pro...
Source
#1Takao Hirano (Shinshu University)H-Index: 12
#2Yuichi Toriyama (Shinshu University)H-Index: 16
Last. Toshinori Murata (Shinshu University)H-Index: 18
view all 9 authors...
Purpose The effect of combination therapy using intravitreal ranibizumab (IVR) injections and short pulse focal/grid laser photocoagulation was evaluated for the treatment of diabetic macular edema (DME).
Source
#1Jeffrey S. HeierH-Index: 59
#2Jean-François Korobelnik (French Institute of Health and Medical Research)H-Index: 38
Last. Frank G. Holz (University of Bonn)H-Index: 91
view all 21 authors...
Purpose To compare efficacy and safety of intravitreal aflibercept injection (IAI) with macular laser photocoagulation for diabetic macular edema (DME) over 3 years. Design Two similarly designed phase 3 trials: VISTA DME and VIVID DME . Participants Patients (eyes; n = 872) with central-involved DME. Methods Eyes received IAI 2 mg every 4 weeks (2q4), IAI 2 mg every 8 weeks after 5 monthly doses (2q8), or laser control. From week 24, if rescue treatment criteria were met, IAI patients received ...
Source
#1Jason Oke (University of Oxford)H-Index: 14
#2Irene M StrattonH-Index: 59
Last. Peter H ScanlonH-Index: 26
view all 5 authors...
AIMS: We aimed to use longitudinal data from an established screening programme with good quality assurance and quality control procedures and a stable well-trained workforce to determine the accuracy of grading in diabetic retinopathy screening. METHODS: We used a continuous time-hidden Markov model with five states to estimate the probability of true progression or regression of retinopathy and the conditional probability of an observed grade given the true grade (misclassification). The true ...
Source
Cited By6
Newest
#1Irini Chatziralli (UoA: National and Kapodistrian University of Athens)H-Index: 21
#2Sara Touhami (University of Paris)H-Index: 7
Last. Panagiotis Theodossiadis (UoA: National and Kapodistrian University of Athens)H-Index: 28
view all 7 authors...
Diabetic retinopathy (DR) is the most common microvascular complication of diabetes mellitus (DM) and the leading cause of blindness in patients with DM. In the pathogenesis of DR, chronic hyperglycemia leads to biochemical and structural alterations in retinal blood vessels' wall, resulting in hyperpermeability and non-perfusion. Since vascular endothelial growth factor (VEGF) has been found to play a significant role in the pathogenesis of DR, this review sheds light on the effect of intravitr...
Source
#1Supriya DabirH-Index: 9
#2Mohan RajanH-Index: 1
Last. Tos T. J. M. BerendschotH-Index: 56
view all 7 authors...
Purpose Diabetic macular oedema (DME) is a vision-threatening complication of diabetic retinopathy. Spectral domain optical coherence tomography angiography (OCTA) is useful for assessing DME. We performed serial OCTA measurements before and after 3 monthly intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections to understand its relationship with best corrected visual acuity (BCVA), central macular thickness (CMT) and vascular indices. Methods OCTA assessment consisting of 6...
Source
Diabetic retinopathy (DR) is one of the most severe complications of diabetes mellitus, its treatment involves specialists of different areas - endocrinologists, diabetes specialists, therapists, cardiologists, surgeons, anesthesiologists etc. For ophthalmologists the objective is to diagnose ocular pathological changes associated with diabetes mellitus, and to prescribe required treatment in a timely manner. Treatment methods used in DR can be divided into three main groups: laser coagulation o...
Source
#1Atsushi Ichio (Mie University)H-Index: 3
#2Masahiko Sugimoto (Mie University)H-Index: 2
Last. Mineo Kondo (Mie University)H-Index: 55
view all 6 authors...
Purpose To determine the effectiveness of intravitreal aflibercept (IVA) on the retinal function in eyes with diabetic macular edema (DME). Methods Twenty-five eyes of 25 patients with DME were treated with three consecutive monthly IVA injections. The retinal sensitivities (RS) within the central 10° were determined by microperimetry (MP). The central subfield macular thickness (CMT) was determined by optical coherence tomography, and the implicit times (IT) and amplitudes (Amp) of the flicker ...
Source
#1Shinichiro Chujo (Mie University)H-Index: 1
#2Masahiko Sugimoto (Mie University)H-Index: 16
Last. Mineo Kondo (Mie University)H-Index: 55
view all 9 authors...
Background: To compare the effectiveness of intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) performed with the treat-and-extend (TAE) regimen on eyes with diabetic macular edema (DME). Patients and methods: This is a retrospective study of 125 eyes of 125 treatment-naive DME patients who received anti-VEGF injections at three consecutive monthly intervals as the loading phase. The changes in the best-corrected visual acuity (BCVA), central retinal thickness (CRT), diabetic reti...
Source
#1Sam E. Mansour (GW: George Washington University)H-Index: 5
#2David J. BrowningH-Index: 46
Last. Abdhish R. BhavsarH-Index: 11
view all 5 authors...
Purpose: To review the current therapeutic options for the management of diabetic retinopathy (DR) and diabetic macular edema (DME) and examine the evidence for integration of laser and pharmacotherapy. Methods: A review of the PubMed database was performed using the search terms diabetic retinopathy, diabetic macular edema, neovascularization, laser photocoagulation, intravitreal injection, vascular endothelial growth factor (VEGF), vitrectomy, pars plana vitreous surgery, antiangiogenic therap...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.